-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Reinstates Buy on Madrigal Pharmaceuticals, Announces $704 Price Target

Benzinga·09/24/2026 12:42:02
Goldman Sachs analyst Andrea Newkirk reinstates Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and announces $704 price target.